MA40462A - Méthode de traitement de la dépression - Google Patents

Méthode de traitement de la dépression

Info

Publication number
MA40462A
MA40462A MA040462A MA40462A MA40462A MA 40462 A MA40462 A MA 40462A MA 040462 A MA040462 A MA 040462A MA 40462 A MA40462 A MA 40462A MA 40462 A MA40462 A MA 40462A
Authority
MA
Morocco
Prior art keywords
treatment
depression
snp
genotype
patient
Prior art date
Application number
MA040462A
Other languages
English (en)
Inventor
Wayne C Drevets
Qingqin S Li
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40462A publication Critical patent/MA40462A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement de la dépression, par exemple, de la dépression résistante au traitement dans le cadre de laquelle le schéma de traitement est ajusté en fonction du génotype du patient au niveau du polymorphisme mononucléotidique (snp) rs4306882. Cette méthode comprend, plus précisément, les étapes consistant à déterminer la présence d'un allèle g ou t au niveau du snp rs4306882 et à administrer un schéma posologique à base de kétamine ou d'eskétamine, ledit schéma
MA040462A 2014-08-13 2015-08-12 Méthode de traitement de la dépression MA40462A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462036896P 2014-08-13 2014-08-13

Publications (1)

Publication Number Publication Date
MA40462A true MA40462A (fr) 2017-06-21

Family

ID=55301311

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040462A MA40462A (fr) 2014-08-13 2015-08-12 Méthode de traitement de la dépression

Country Status (11)

Country Link
US (1) US10098854B2 (fr)
EP (1) EP3179993B1 (fr)
JP (1) JP6545788B2 (fr)
KR (1) KR20170040800A (fr)
CN (1) CN106714789A (fr)
AU (2) AU2015301782B2 (fr)
CA (1) CA2957926A1 (fr)
IL (2) IL250490A0 (fr)
MA (1) MA40462A (fr)
MX (1) MX2017001908A (fr)
WO (1) WO2016025581A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
CA2936809A1 (fr) * 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprenant de la ketamine pour le traitement d'un trouble du spectre de l'autisme
CA2961208A1 (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Regimes posologiques specifiques au genotype val66met (snp rs6265) et methodes pour le traitement de la depression
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019094596A1 (fr) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarqueurs pour l'efficacité de traitements prophylactiques contre des troubles affectifs induits par le stress
MX2020006650A (es) * 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CA3099293A1 (fr) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methodes de traitement de la toxicomanie
EP3628313B1 (fr) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Composition de kétamine pour utilisation dans un procédé de traitement de la dépression par administration pulmonaire
SG11202107978RA (en) 2019-01-23 2021-08-30 Univ Michigan Regents Methods and system for the reconstruction of drug response and disease networks and uses thereof
WO2020178653A1 (fr) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Eskétamine pour le traitement de la dépression
US20210407643A1 (en) * 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
JP2024516827A (ja) 2021-04-30 2024-04-17 マインド メディシン， インコーポレイテッド Ｌｓｄ塩結晶形態
AU2022331315B2 (en) 2021-08-19 2025-10-16 Definium Therapeutics US, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
RU2224523C2 (ru) 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (fr) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
EP1551393A4 (fr) 2002-07-30 2010-06-16 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
KR102035877B1 (ko) * 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
WO2013138322A1 (fr) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Eskétamine dans le traitement de la dépression réfractaire ou résistante aux traitements
AU2013305580A1 (en) 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
WO2016025581A1 (fr) 2016-02-18
JP2017524719A (ja) 2017-08-31
MX2017001908A (es) 2017-08-08
AU2020281101A1 (en) 2021-01-07
US20160045455A1 (en) 2016-02-18
IL250490A0 (en) 2017-03-30
EP3179993A4 (fr) 2018-03-28
EP3179993B1 (fr) 2021-01-20
JP6545788B2 (ja) 2019-07-17
AU2015301782B2 (en) 2020-09-03
KR20170040800A (ko) 2017-04-13
IL279627A (en) 2021-03-01
EP3179993A1 (fr) 2017-06-21
US10098854B2 (en) 2018-10-16
CN106714789A (zh) 2017-05-24
AU2015301782A1 (en) 2017-03-02
CA2957926A1 (fr) 2016-02-18

Similar Documents

Publication Publication Date Title
IL279119A (en) VAL66MET genotype-specific dosage regimens (SNP rs6265) and methods for treating depression
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
MY206629A (en) Detection processes using sites of chromosome interaction
MX2020013278A (es) Analogos de nucleotidos.
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12014502094A1 (en) Substituted nucleosides, nucleotides and analogs thereof
LT3265102T (lt) Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui
FR3028512B1 (fr) Procede d'hydrosilylation mettant en œuvre un catalyseur organique derive de germylene
MX2017001908A (es) Metodo para el tratamiento de la depresion.
EP3212658A4 (fr) Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
PH12016500492B1 (en) Pyridazinone compounds and uses thereof
BR112017006680A2 (pt) variantes de vírus influenza a
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
HUE046116T2 (hu) Biotin, demielinizációs neuropátiák kezelésére
MX2016017124A (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
WO2015109318A3 (fr) Méthodes thérapeutiques
WO2015134599A3 (fr) Composés de platine(iv) et procédés de preparation et d'utilisation de ceux-ci
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX385963B (es) Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona.
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease